Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05982886 · ClinicalTrials.gov registry record
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,093
- Enrollment target
NCT05982886 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,093 participants.
The verdict
NCT05982886 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,093 participants
- Enrollment target
Study Summary
This was a retrospective observational study of patients with advanced breast cancer (BC). This non-interventional study was conducted using discrete structured data and medical record abstraction, if needed, from patients treated at Texas Oncology, the designated research organization and a community oncology practice. The first date of a new diagnosis of advanced BC (de novo or progressed to advanced BC) defined the study index date. To allow for an adequate potential duration of follow-up (retrospectively observed) after the index date over which PIK3CA testing and treatment patterns was observed, a minimum follow-up opportunity of 6 months after the diagnosis of advanced BC at the time of data pull and/or abstraction was required.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,093 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2021-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05982886
The ClinicalTrials.gov registry entry for NCT05982886 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,093 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05982886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05982886 about?
NCT05982886 is a clinical study titled "Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer". This was a retrospective observational study of patients with advanced breast cancer (BC). This non-interventional study was conducted using discrete structured data and medical record abstraction, if needed, from patients treated at Texas Oncology, the designated research organization and a communi...
What is the current status of trial NCT05982886?
This trial is currently completed. The enrollment target is 1,093 participants. The study started on 2021-01-15. Estimated completion is 2021-04-01.
Who is sponsoring clinical trial NCT05982886?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.